May 4, 2022 -- RedShift BioAnalytics has launched its novel Apollo technology for advanced microfluidic modulation spectroscopy (MMS). This technology enables highly sensitive and precise measurement of biomolecules with improved efficiency and decreased sample volume compared to the company's previous AQS3 pro structural analysis technology.
Through the use of its updated software and analytics capabilities, Apollo characterizes the structural attributes of biomolecules in a reproducible manner with a broad concentration range from 0.1 mg/mL to greater than 200 mg/mL. Additionally, the technology reduces background noise and interference of excipients using real-time buffer subtraction. Through these features, Apollo supports the analysis and structural comparisons between various molecules, including viral vectors, mRNA, and antibody drug conjugates. This provides great utility in the discovery, screening, formulation, and quality control processes during drug development.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: